# First-in-Human Study of ICT01 in Patients With Advanced Cancer

> **NCT04243499** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ImCheck Therapeutics** · enrollment: 292 (actual)

## Conditions studied

- Solid Tumor, Adult
- Hematopoietic/Lymphoid Cancer

## Interventions

- **BIOLOGICAL:** IV ICT01

## Key facts

- **NCT ID:** NCT04243499
- **Lead sponsor:** ImCheck Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-05
- **Primary completion:** 2025-10-15
- **Final completion:** 2026-10
- **Target enrollment:** 292 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04243499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04243499, "First-in-Human Study of ICT01 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04243499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*